COMMENT
In cases of prostate cancer investigation MRI can be used during a prostate biopsy to help guide the needles into the prostate. This paper of the group of Dr. Abreu and Gill (11 Ramacciotti LS, Strauss D, Cei F, Kaneko M, Mokhtar D, Cai J, Jadvar D, Cacciamani GE, Aron M, Halteh PB, Duddalwar V, Gill I, Abreu AL. Transperineal versus Transrectal MRI/TRUS fusion-guided prostate biopsy in a large, ethnically diverse, and multiracial cohort. Int Braz J Urol. 2024; 50:616-28. doi: 10.1590/S1677-5538.IBJU.2024.0354.
https://doi.org/10.1590/S1677-5538.IBJU....
) shows the importance of MRI in the prostate cancer diagnosis. In the last years several papers studied the prostate biopsy showing the superiority of the perineal MRI/TRUS Fusion-Guided Prostate Biopsy (22 Lv Z, Wang J, Wang M, Hou H, Song L, Li H, et al. Is it necessary for all patients with suspicious lesions undergo systematic biopsy in the era of MRI-TRUS fusion targeted biopsy? Int Braz J Urol. 2023;49:359-71. doi: 10.1590/S1677-5538.IBJU.2023.0060.
https://doi.org/10.1590/S1677-5538.IBJU....
–44 Andrade GM, Sesconetto L, da Silva RBR, Dos Santos GGR, Kayano PP, Baccaglini W, et al. Impact of COVID-19 pandemic on prostate cancer outcomes at an uro-oncology referral center. Int Braz J Urol. 2023;49:233-42. doi: 10.1590/S1677-5538.IBJU.2022.0393.
https://doi.org/10.1590/S1677-5538.IBJU....
). The group of the University of Southern California compared transperineal (TP) vs transrectal (TR) magnetic resonance imaging (MRI) and transrectal ultrasound (TRUS) fusion-guided prostate biopsy (PBx) in a large, ethnically diverse and multiracial cohort with 1491 patients, with 480 undergoing TP and 1011 TR PBx and concluded that in a large and diverse cohort, black race, but not the biopsy approach, was an independent predictor for clinical significant prostate cancer (CSPCa) detection. TP and TR PBx yielded similar CSPCa detection rates, however the TP PBx was histologically more informative.
REFERENCES
-
1Ramacciotti LS, Strauss D, Cei F, Kaneko M, Mokhtar D, Cai J, Jadvar D, Cacciamani GE, Aron M, Halteh PB, Duddalwar V, Gill I, Abreu AL. Transperineal versus Transrectal MRI/TRUS fusion-guided prostate biopsy in a large, ethnically diverse, and multiracial cohort. Int Braz J Urol. 2024; 50:616-28. doi: 10.1590/S1677-5538.IBJU.2024.0354.
» https://doi.org/10.1590/S1677-5538.IBJU.2024.0354 -
2Lv Z, Wang J, Wang M, Hou H, Song L, Li H, et al. Is it necessary for all patients with suspicious lesions undergo systematic biopsy in the era of MRI-TRUS fusion targeted biopsy? Int Braz J Urol. 2023;49:359-71. doi: 10.1590/S1677-5538.IBJU.2023.0060.
» https://doi.org/10.1590/S1677-5538.IBJU.2023.0060 -
3Gilberto GM, Arcuri MF, Falsarella PM, Mariotti GC, Lemos PLA Neto, Garcia RG. Complication rates of transrectal and transperineal prostate fusion biopsies - is there a learning curve even in high volume interventional center? Int Braz J Urol. 2023;49:334-40. doi: 10.1590/S1677-5538.IBJU.2023.0054.
» https://doi.org/10.1590/S1677-5538.IBJU.2023.0054 -
4Andrade GM, Sesconetto L, da Silva RBR, Dos Santos GGR, Kayano PP, Baccaglini W, et al. Impact of COVID-19 pandemic on prostate cancer outcomes at an uro-oncology referral center. Int Braz J Urol. 2023;49:233-42. doi: 10.1590/S1677-5538.IBJU.2022.0393.
» https://doi.org/10.1590/S1677-5538.IBJU.2022.0393
Publication Dates
-
Publication in this collection
09 Sept 2024 -
Date of issue
Sep-Oct 2024
History
-
Received
10 July 2024 -
Accepted
15 July 2024 -
Published
25 July 2024